CJC-1295 + Ipamorelin Research Guide
A GHRH analogue without DAC paired with the ghrelin receptor agonist ipamorelin, sold as CJC-1295 No DAC + Ipamorelin 10mg. Summarizes the research on each component.
What is CJC-1295 + Ipamorelin?
CJC-1295 was developed as an analogue of human growth hormone-releasing factor (hGRF) 1-29. It is a tetrasubstituted form of hGRF(1-29) that, in its original design, carries an added reactive lysine group (the drug affinity complex, or DAC) that binds to serum albumin and extends its time in circulation (Jettรฉ et al., 2005). The “no DAC” form is the tetrasubstituted hGRF(1-29) peptide without that albumin-binding group.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts at the ghrelin receptor (Raun et al., 1998). We supply the two together in one vial as CJC-1295 No DAC + Ipamorelin 10mg. The two peptides act at different receptors: CJC-1295 at the GHRH receptor and ipamorelin at the ghrelin receptor.
Research areas studied
The findings below come from published cell-based and animal research. They describe what studies have examined and reported, not effects of any research material.
CJC-1295 in rat pituitary and rat studies
Three maleimido derivatives of hGRF(1-29) were bioactive in cultured rat anterior pituitary cells and more stable against the enzyme dipeptidyl peptidase-IV. The selected compound, CJC-1295 with DAC, showed a 4-fold increase in growth hormone area under the curve over 2 hours compared with hGRF(1-29) and was still present in rat plasma beyond 72 hours (Jettรฉ et al., 2005).
CJC-1295 in a mouse model
In mice lacking the GHRH gene, once-daily administration of CJC-1295 (with DAC) for 5 weeks was associated with normal body weight and length, and with increased pituitary growth hormone mRNA (Alba et al., 2006). These studies used the DAC form; we found no comparable published studies of the no-DAC form.
Ipamorelin pharmacology
In primary rat pituitary cells, ipamorelin released growth hormone with potency and efficacy similar to GHRP-6. In swine it did not raise ACTH or cortisol, even at doses far above those needed for growth hormone release, which led the authors to describe it as the first selective growth hormone secretagogue (Raun et al., 1998).
Analytical research, regulatory status and limits
A 2021 study developed a liquid chromatography-tandem mass spectrometry method to detect CJC-1295, CJC-1295 with DAC and other GHRH analogues in urine for anti-doping work (Memdouh et al., 2021). FDA’s compounding safety page lists CJC-1295 among nominated substances whose nominations were withdrawn, citing possible immunogenicity and reported adverse events, and notes that human data are limited. We found no controlled studies of the two peptides combined.
Storage and handling
Like most research peptides, CJC-1295 + Ipamorelin is normally supplied for laboratory use as a lyophilized (freeze-dried) powder in a sealed vial. Check the label and the batch COA for the exact form of your lot. Zero Zero Collection recommends keeping vials refrigerated at 2 to 8 ยฐC and protected from light, as stated on every product page. Let a refrigerated vial reach room temperature before opening it so moisture does not condense on the powder.
When a lab reconstitutes lyophilized material, standard practice is to add a sterile diluent such as bacteriostatic water slowly down the inside wall of the vial, then swirl gently rather than shake. The volume depends on the concentration a protocol calls for, so follow your own lab’s validated method. Label the vial with the date, keep reconstituted material refrigerated, and follow your institution’s guidance on how long a solution stays usable.
Quality and documentation
We supply CJC-1295 + Ipamorelin as research material in a sealed, lot-traceable vial. Match the lot number on your vial to your order records, and contact our team at [email protected] with any lot-specific questions.
CJC-1295 + Ipamorelin FAQ
What does "no DAC" mean?
DAC stands for drug affinity complex, an added lysine group that binds CJC-1295 to serum albumin and lengthens its time in circulation. The no-DAC form is the peptide without that group.
Do CJC-1295 and ipamorelin act on the same receptor?
No. CJC-1295 is an analogue of growth hormone-releasing factor and acts at the GHRH receptor. Ipamorelin acts at the ghrelin receptor.
Has the combination been studied?
We found no controlled published studies of the two peptides combined. Published research covers each component separately.
References
- Jettรฉ L, Lรฉger R, Thibaudeau K, et al. (2005). Endocrinology. PubMed 15817669
- Alba M, Fintini D, Sagazio A, et al. (2006). Am J Physiol Endocrinol Metab. PubMed 16822960
- Raun K, Hansen BS, Johansen NL, et al. (1998). Eur J Endocrinol. PubMed 9849822
- Memdouh S, Gavriloviฤ I, Ng K, et al. (2021). Drug Test Anal. PubMed 34665524
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed October 28, 2026. fda.gov
For research use only. Not for human consumption. This guide summarizes published scientific literature for laboratory research context. It is not medical advice, dosing guidance or a claim of safety or effectiveness for any use in people or animals.